CME Institute

Available courses

Assessing Progress in FSHD Treatment Options: Unraveling Challenges and Measuring Outcomes Live

This CME activity took place on Thursday, October 16, 2024, and is eligible for AMA PRA Category 1 Credits™ only to those who attended the activity virtually on this date.

Program Introduction

Join Leo Wang and Maya Hatch for an insightful journey into the world of Facioscapulohumeral Muscle Dystrophy (FSHD), covering its etiology, clinical presentations, and the complexities of assessing treatment outcomes in clinical trials. Key focuses include the innovative Reachable Workspace (RWS) metric for functional assessment, the impact of current clinical trials, and emerging therapeutic targets. Discussions will also highlight biomarker insights, disease mechanisms like DUX4 regulation, and future strategies for FSHD management. Don’t miss this opportunity to gain insights from experts shaping the future of FSHD research and care, along with perspective from a real-world patient living with FSHD.

Learning Objectives

Evaluate the use of RWS as an outcome measure for FSHD clinical trials to measure disease progression, impact on ADLs, and effect of therapy
Discuss the mechanism of FSHD disease that leads to challenges in DUX4 biomarker detection

Available Credit

1.00 AMA PRA Category 1 Credit^TM
1.00 Participation

A Tailored Approach to Diagnosis and Early Treatment in Patients with Duchenne Muscular Dystrophy: A Real-World View of Quality of Life

Program Introduction

A detailed, modern digest of key advances in the diagnosis, treatment, and management of patients with Duchenne muscular dystrophy.

Learning Objective

After completing this educational activity, you should be able to:

Use expert-guided treatment strategies for patients with Duchenne muscular dystrophy.

Available Credit

0.50 AMA PRA Category 1 Credit™
0.50 Participation

Best Practices for Management of Mental Health in Women: Focusing on Mood Disorders Throughout the Lifespan

Program Introduction

Diagnosis and tailored treatment of menstrual cycle- and menopausal-related mood disorders are key factors in helping women live the lives they want to live.

Learning Objectives

Appraise the influence of the reproductive stage on mood disorders and comorbid psychiatric conditions in women.
Assess factors involved in the diagnoses of mood disorders in women and the differential diagnoses and common comorbidities.
Summarize evidence-based approaches for diagnosing and treating mood disorders in women.

Available Credit

1.00 AMA PRA Category 1 Credit™
1.00 Participation

Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports

Program Introduction

LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.

Learning Objectives

After completing this educational activity, you should be able to:

Examine data comparing the efficacy of LAIAs and oral medications.
Analyze the clinical trial data and unique considerations of available LAIAs.
Implement early integration of LAIA therapies in appropriate patients.

Available Credit

1.00 AMA PRA Category 1 Credit™
1.00 Participation

Case Studies in HAE: Diagnosing, Treating, and Managing the Patient With Hereditary Angioedema

Program Introduction

Explore Hereditary Angioedema treatment, emphasizing individualized care, first-line therapeutic options and investigational agents in clinical development.

Learning Objectives

Analyze Hereditary Angioedema’s (HAE) pathophysiology to explain its underlying mechanisms.
Evaluate the impact of HAE on affected individuals to appreciate the condition's severity and implications.
Compare and contrast different therapeutic options available for HAE to determine their effectiveness.
Investigate and predict developments in future therapies for HAE to understand the direction of medical research and potential innovations.

Available Credit

1.00 AMA PRA Category 1 Credit™
1.00 Participation

Optimizing Mental Health for Women: Recognizing and Treating Mood Disorders Throughout the Lifespan

Program Introduction

Mood disorders throughout women's reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.

Learning Objectives

After completing this educational activity, you should be able to:

Appraise the influence of the reproductive stage on mood disorders and comorbid psychiatric conditions in women
Assess factors involved in the diagnoses of mood disorders in women and the differential diagnoses and common comorbidities
Summarize evidence-based approaches for diagnosing and treating mood disorders in women

Available Credit

1.00 AMA PRA Category 1 Credit™
1.00 Participation

Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management

Program Introduction

What is the future of schizophrenia treatment? An in-depth exploration of novel, non-dopaminergic therapies transforming the standard of care for patients with schizophrenia’s positive and negative symptoms.

Learning Objectives

After completing this educational activity, you should be able to:

Outline current medication classes used in the treatment of schizophrenia
Articulate side effect development and negative symptom control challenges associated with standard-of-care antipsychotics
Review the latest research describing the biologic rationale of novel non-dopaminergic pathways in schizophrenia
Analyze emerging clinical trial data for non-dopamine-targeting schizophrenia therapies

Available Credit

1.00 AMA PRA Category 1 Credit™
1.00 Participation

Neuropsychiatric Complications of Parkinson’s Disease Psychosis

Program Introduction

Join us for a dynamic one-hour CME activity on Parkinson’s Disease Psychosis (PDP) with top experts Mark F. Lew, MD, and Jennifer Hui, MD. Unlock the latest best practices for diagnosing PDP and implementing cutting-edge therapies. The session kicks off with a deep dive into Parkinson’s Disease, covering its prevalence, motor and nonmotor symptoms, and the unique challenges of PDP. Next, master the intricacies of recognizing and diagnosing PDP with the newest diagnostic criteria and screening tools. Finally, conquer PDP treatment and management strategies, including behavioral approaches, medication adjustments, and safe antipsychotic options. Plus, gain invaluable insights from the caregiver of a real-world patient with PDP, providing a firsthand perspective on managing this complex condition. Boost your clinical expertise and transform patient care with this essential update on managing Parkinson’s Disease Psychosis.

Learning Objectives

Identify appropriate best practices for the diagnosis of PDP
Implement evidence-based current therapies for patients with PDP

Available Credit

1.00 AMA PRA Category 1 Credit^TM
1.00 Participation

Advancements in Understanding Facioscapulohumeral Muscular Dystrophy (FSHD) and What Clinically Meaningful Outcomes Look Like

Program Introduction

Delve into the cutting-edge advancements in Facioscapulohumeral Muscular Dystrophy (FSHD) alongside the dynamic duo of Dr. Leo H. Wang and Dr. Maya N. Hatch in this symposium recorded at the 2024 MDA Clinical & Scientific Conference Summit. Positioned as the third most prevalent muscular dystrophy, FSHD stands as a genetic enigma with intricate roots, showcasing a progressive saga of asymmetrical muscle weakness. Initially targeting the facial and shoulder muscles before spreading its grip onto the extremities, this disorder's clinical narrative presents a formidable challenge in quantifying outcomes. It's an imperative moment to unearth dependable and sensitive metrics for clinical trials, navigating the labyrinthine landscape of FSHD. Acquire invaluable insights into mastering daily functionalities, tackling complications head-on, and remain abreast of the latest breakthroughs in establishing rock-solid measures for gauging progress.

Learning Objectives

Evaluate the use of RWS as an outcome measure for FSHD clinical trials and translate changes in RWS to clinically meaningful outcomes
Discuss the mechanism of FSHD disease that leads to challenges in DUX4 biomarker detection

Available Credit

1.00 AMA PRA Category 1 Credit^TM
1.00 Participation

2024 Manuscript Peer Review for Physicians Postgraduate Press, Inc. (The Journal of Clinical Psychiatry | The Primary Care Companion for CNS Disorders)

CME credit for physicians or CE participation credit for nonphysicians is awarded for reviews submitted in a timely manner and in recognition of the learning that takes place during a manuscript review.

You will be awarded 3.00 AMA PRA Category 1 Credit^TM for this activity. The ACCME allows up to 15.00 AMA PRA Category 1 Credit^TM for peer review to be claimed each year.

Learning Objective

We anticipate learners will make improvements in their ability to critically review research manuscripts, as well as incorporate new research findings into their own practice as appropriate.

Financial Disclosure

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:

	*Larry Culpepper, MD, MPH (Editor in Chief, The Primary Care Companion for CNS Disorders)*, is affiliated with the Department of Family Medicine, Boston University School of Medicine, Boston, Massachusetts, and in the past year, has been an advisor for AbbVie, Eisai, and Supernus; has been a stock shareholder of M-3 Information; and has received royalties from UpToDate.
	*Marlene P. Freeman, MD (Editor in Chief, The Journal of Clinical Psychiatry [JCP])*, is affiliated with Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts (MGH) and works with the MGH National Pregnancy Registry for which the current sponsors are Alkermes, Inc. (2016-Present); Aurobindo Pharma (2020-Present); AuroMedics Pharma LLC (2021-present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Sunovion Pharmaceuticals, Inc. (2011-Present); Supernus Pharmaceuticals (2021-Present); and Teva Pharmaceutical Industries Ltd. (2018-Present). Past Sponsors were Forest/Actavis/Allergan (2016-2018, declined to sponsor: 2018-Present), AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); and Pfizer Inc (2009-2011, declined to sponsor: 2012-Present). As an employee of MGH, Dr Freeman works with the MGH CTNI, which has received research funding from multiple pharmaceutical companies and NIMH. Dr Freeman has also received research support from Investigator Initiated Trials /Research: JayMac and Sage; been on the advisory boards for Eliem and Sage and Independent Data Safety and Monitoring Committees: Janssen (Johnson & Johnson), Novartis, and Neurocrine; received honoraria for speaking and planning of educational activities for WebMD, Medscape, Pri-Med, and Postpartum Support International; and received Scale Royalties (through MGH) for The Massachusetts General Hospital Female Reproductive Lifecycle and Hormones Questionnaire (Freeman et al. 2013).
	Philippe Courtet, MD, PhD (JCP Section Editor, Focus on Suicide), is affiliated with FondaMental Fondation, Créteil, France, and has received consulting fees from Pfizer Inc, honoraria for speaking/teaching from Janssen Cilag, and advisory board fees from Ethypharm Digital Therapy and Janssen Cilag in the past 24 months.
	Jordan F. Karp, MD (JCP Section Editor, Focus on Geriatric Psychiatry), is affiliated with the Department of Psychiatry, College of Medicine, University of Arizona, Tucson, Arizona; owns equity interest/stocks in privately held company Aifred Health and has received grant/research support from NIH and PCORI (Patient-Centered Outcomes Research Institute) and advisory board fees from Biogen, which has now ended.
	Joseph F. Goldberg, MD (JCP Section Editor, Early Career Psychiatrists), is affiliated with the Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York; has received consulting fees from BioXcel, Lundbeck, Otsuka, Sage Pharmaceuticals, Sunovion, and Supernus; honoraria for speaking/teaching from Abbvie, Alkermes, Axsome, Intracellular Therapies, and Sunovion; and royalties from American Psychiatric Publishing and Cambridge University Press. He is on the advisory board for Jazz Pharmaceuticals.
	Ann K. Shinn, MD, MPH (JCP Section Editor, Focus on Psychosis), is affiliated with the Psychotic Disorders Division, McLean Hospital/Harvard Medical School Department of Psychiatry, Belmont, Massachusetts, and has no financial relationships with any ACCME-defined ineligible company in the past 24 months.
	Gary W. Small, MD (JCP Section Editor, Focus on Geriatric Psychiatry), is affiliated with Hackensack Meridian Health, Hackensack University Medical Center Edison, New Jersey, and has received consulting and advisory board fees from AARP, Acadia, Allergan, Avanir, Biogen, Gerontological Society of America, Handok, Herbalife, Lundbeck, Lilly, McCormick Science Institute, Otsuka, Reckitt Benckiser, Roche, and Theravalues.
	Karen D. Wagner, MD, PhD (JCP Section Editor, Focus on Childhood and Adolescent Mental Health), is affiliated with the Department of Psychiatry and Behavioral Sciences, The University of Texas Medical Branch, Galveston, Texas, and has no financial relationships with any ACCME-defined ineligible company in the past 24 months.

To be awarded credit and receive a certificate for this activity, peer-review learners must have completed their peer review in a timely manner and have provided constructive criticism to the author and Editor. The peer reviewer must complete the following Evaluation form to claim credit.

You will be awarded 3.00 AMA PRA Category 1 CreditTM for this activity. The ACCME allows up to 15.00 AMA PRA Category 1 Credit^TM for peer review to be claimed each year.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this manuscript review activity for a maximum of 3.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the Evaluation.

No financial support has been received for this activity.

Available Credit

3.00 AMA PRA Category 1 Credit™
3.00 Participation

All courses